Desmopressin nasal drops: Discontinuation
The supplier is discontinuing desmopressin (Minirin) nasal drops 0.1 mg/ml because they cannot source one of the primary packaging materials.
There has been difficulty sourcing desmopressin nasal drops (p/code 207489) since 2020. To mitigate this issue, we listed desmopressin wafers (Minirin Melt p/code 2603268) on 1 January 2021 and removed funding criteria from all other presentations of desmopressin.
The Endocrinology Subcommittee of PTAC (the Pharmacology and Therapeutics Advisory Committee) provided independent clinical advice. They advised that desmopressin wafers are an appropriate alternative presentation.
18 August 2021: Discontinuation announced
The supplier has advised us that desmopressin (Minirin) nasal drops 0.1 mg/ml have been discontinued as one of the primary packaging materials cannot be sourced.
Minirin nasal drops will be de-listed from the Pharmaceutical Schedule from 1 January 2022. We understand that there is little or no stock in the supply chain.
This discontinuation does not affect other presentations of desmopressin. They remain available.